Suppr超能文献

热休克蛋白 90(HSP90)抑制对人肝细胞和实验模型中肝再生的影响。

Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models.

机构信息

Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany.

出版信息

Surgery. 2010 May;147(5):704-12. doi: 10.1016/j.surg.2009.10.061. Epub 2009 Dec 16.

Abstract

BACKGROUND

Targeting heat shock protein 90 (HSP90) has gained great interest for cancer therapy. However, in view of novel multimodality therapy approaches for treating hepatic metastases, concerns have raised regarding the impact of targeted therapies on liver regeneration and repair. In this study, we investigated the impact of HSP90 inhibition on liver regeneration in murine models.

METHODS

Effects of HSP90 inhibition on the activation of signaling intermediates, expression of vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) were investigated in primary human hepatocytes (PHHs) in vitro. Effects of HSP90 inhibition on liver regeneration and repair were determined in a murine hepatectomy model and in a model with acute carbon tetrachloride (CCl(4))-induced liver damage.

RESULTS

Inhibition of HSP90 effectively diminished the constitutive phosphorylation of Akt, Erk, and STAT3 in PHHs. Conversely, inhibition of HSP90 significantly increased the expression of both VEGF and HGF mRNA, and induced HSP70 protein in PHH cultures in vitro. In vivo, HSP90 inhibition significantly upregulated constitutive VEGF mRNA and HSP70 in murine livers and did not impair liver re-growth after 70% hepatectomy. Furthermore, BrdUrd-staining and histological quantification of necrotic areas revealed that HSP90 inhibition did not impair liver regeneration following partial hepatectomy, or liver repair that occurs after toxic liver injury with CCl(4).

CONCLUSION

Targeting HSP90 does not negatively affect the multifactorial process of liver regeneration and repair in vivo. Hence, the use of inhibitors to HSP90 appears to be a valid option for neoadjuvant therapy of liver metastases when subsequent surgery is intended.

摘要

背景

针对热休克蛋白 90(HSP90)的治疗已成为癌症治疗的热点。然而,鉴于针对肝转移的新型多模态治疗方法,人们对靶向治疗对肝再生和修复的影响产生了担忧。在这项研究中,我们研究了 HSP90 抑制对鼠模型中肝再生的影响。

方法

在体外原代人肝细胞(PHH)中研究 HSP90 抑制对信号转导中间物的激活、血管内皮生长因子(VEGF)和肝细胞生长因子(HGF)的表达的影响。在鼠肝部分切除术模型和急性四氯化碳(CCl4)诱导的肝损伤模型中,确定 HSP90 抑制对肝再生和修复的影响。

结果

HSP90 的抑制可有效减少 PHH 中 Akt、Erk 和 STAT3 的组成性磷酸化。相反,HSP90 的抑制显著增加了 VEGF 和 HGF mRNA 的表达,并在体外 PHH 培养物中诱导 HSP70 蛋白。在体内,HSP90 的抑制可显著上调鼠肝中组成性 VEGF mRNA 和 HSP70,且不影响 70%肝切除术后的肝再生长。此外,BrdUrd 染色和坏死区域的组织学定量分析表明,HSP90 的抑制并不影响部分肝切除术后的肝再生,或 CCl4 诱导的肝毒性后发生的肝修复。

结论

靶向 HSP90 不会对体内肝再生和修复的多因素过程产生负面影响。因此,当计划进行后续手术时,HSP90 抑制剂的使用似乎是肝转移新辅助治疗的有效选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验